Every Form 4 that Context Therapeutics Inc. (CNTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTX filings page.
Context Therapeutics Inc. director Andy Pasternak received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $0.576 per share and expire on June 23, 2036. Following this grant, he holds 45,000 options directly.
The option vests and becomes exercisable on the earlier of June 24, 2027, which is the one-year anniversary of the grant date, or the company’s 2027 annual meeting of stockholders, subject to his continued service with the company.
Context Therapeutics Inc. director Stacey Jennifer Evans received a stock option grant covering 45,000 shares of common stock. The option has an exercise price of $0.576 per share and was awarded as a compensation-related grant, not an open-market purchase.
The option vests and becomes exercisable on the earlier of June 24, 2027, or the company’s 2027 annual meeting of stockholders, subject to her continued service with the company. Following this grant, Evans holds stock options for 45,000 shares directly under this award.
Context Therapeutics director Linda West received a new stock option grant as part of her compensation. She was awarded options to acquire 45,000 shares of common stock at an exercise price of $0.576 per share, expiring on June 23, 2036.
The option vests and becomes exercisable on the earlier of June 24, 2027, or the company’s 2027 annual meeting of stockholders, and is subject to her continued service with Context Therapeutics. After this grant, she holds stock options for 45,000 underlying shares directly.
Context Therapeutics Inc. director Karen L. Smith reported receiving a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $0.576 per share and expire on June 23, 2036.
According to the grant terms, the option vests and becomes exercisable on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders, subject to her continued service. Following this award, she holds options to acquire 45,000 shares directly.
Context Therapeutics Inc. director Luke Nathaniel Walker received a grant of 45,000 stock options to buy Common Stock at an exercise price of $0.576 per share. The options vest on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders and expire on June 23, 2036.
Context Therapeutics Inc. director Philip W. Kantoff reported a new stock option grant. He received options to buy 45,000 shares of common stock at an exercise price of $0.5760 per share, bringing his reported derivative holdings in this grant to 45,000 options.
The option vests and becomes exercisable on the earlier of June 24, 2027, the one-year anniversary of the grant date, or the company’s 2027 annual meeting of stockholders, subject to his continued service with the company. The options expire on June 23, 2036. This is a compensation-related award, not an open-market purchase or sale.
Levit Alex C. reported acquisition or exercise transactions in this Form 4 filing.
Context Therapeutics Inc. reported that Chief Legal Officer and Corporate Secretary Alex C. Levit received a grant of stock options covering 270,000 shares on February 19, 2026. According to the terms, 25% of the options vest on February 19, 2027, with the remainder vesting in equal monthly installments over the following three years, conditioned on continued service.
Minai-Azary Jennifer Lynn reported acquisition or exercise transactions in this Form 4 filing.
Context Therapeutics Inc. reported an insider equity award to its Chief Financial Officer, Jennifer Lynn Minai-Azary. She received a stock option covering 275,000 shares of common stock as a grant, not an open-market purchase or sale.
According to the terms, the option vests over four years. 25% of the option vests and becomes exercisable on February 19, 2027, with the remaining balance vesting in equal monthly installments over the following three years, subject to her continued service with the company.
Context Therapeutics Inc. reported that Chief Medical Officer Karen Deborah Chagin acquired a grant of stock options covering 290,000 shares of the company’s stock. The options carry a reported exercise price of $0.0000 per share and are held as direct derivative securities.
According to the vesting terms, 25% of the option award vests and becomes exercisable on February 19, 2027, with the remaining balance vesting in equal monthly installments over the following three years, contingent on her continued service with the company.
Context Therapeutics Inc. reported that Chief Executive Officer Martin A. Lehr received a grant of stock options for 815,000 shares at an exercise price of $0.00 per share. The option vests over four years, with 25% vesting on February 19, 2027 and the rest in equal monthly installments over the following three years, contingent on continued service.